Skip to main content
. 2024 Jun 10;7(3):387–400. doi: 10.31662/jmaj.2023-0214

Table 1.

Characteristics of the Participants in This Cohort Study.

Variable Overall (n = 39) DPP4i add-on group (n = 20) SGLT2i add-on group (n = 19) P
Number (male/female) 20/19 11/9 9/10 0.75
Age (years) 64 ± 11 61 ± 12 67 ± 10 0.079
 ≥65 years of age, n (%) 18 (46%) 7 (35%) 11 (58%) 0.20
 <65 years of age, n (%) 21 (54%) 13 (65%) 8 (42%) 0.20
Duration of diabetes (years) 12 ± 8 12 ± 7 12 ± 9 0.58
Diabetes-associated complications
 Retinopathy 4 2 2 >0.99
 Neuropathy 8 4 4 >0.99
 Nephropathy 11 3 8 0.082
Medications for diabetes mellitus
 Metformin 24 15 9 0.10
 Sulfonylurea 10 6 4 >0.99
 Insulin 5 3 2 >0.99
 α-Glucosidase inhibitor 1 1 0 >0.99
Grip strength (kg) 27.5 ± 9.6 30.3 ± 10.4 24.5 ± 8.3 0.058
Calf circumference (cm)
 Right 36.9 ± 3.6
(n = 37)
36.9 ± 3.7
(n = 18)
36.9 ± 3.6
(n = 19)
0.98
 Left 37.0 ± 3.1
(n = 37)
36.8 ± 3.3
(n = 18)
37.2 ± 3.1
(n = 19)
0.75
Adherence to medication score 7 (6-7) 7 (6-7) 7 (6-7) 0.98§
GDS5 (total score) 1 (0-3) 1 (0-2) 0 (0-3) 0.25§
IPAC-SF 2 (total physical activity score) 792 (240-2,919) 1,053 (478-4,345) 438 (66-2,772) 0.050§

Continuous variables that showed a normal or nonnormal distribution are expressed as mean ± SD or median (interquartile range (IQR)). Values were compared between the DPP4i and SGLT2i add-on groups using Fisher’s exact test (†), Student’s t-test (‡), or Mann-Whitney U test (§)

DPP4i, dipeptidyl peptidase-4 inhibitor; GDS5, Geriatric Depression Scale 5; IPAC-SF, International Physical Activity Questionnaire Short Form 2; SGLT2i, sodium-glucose cotransporter-2 inhibitor